Request Trial

Marisa Woutersen

Key details

Marisa Woutersen is a senior reporter for Life Sciences Intellectual Property Review and World IP Review. She largely covers intellectual property developments across the global life sciences sector, including pharmaceuticals, biotechnology, medtech, AI, M&A and regulation.

Since joining Newton Media in 2023, Marisa has reported across a wide range of topics, from the rise of generative AI and its impact on the creative industries to the crossover between intellectual property and sport, including issues affecting athletes, as well as global pharmaceutical disputes, vaccine technology, access to medicines and life sciences M&A.

She has reported live from court and regularly travels to international conferences, where she interviews lawyers, business leaders and other key industry figures.

Marisa holds a Master’s in International Law and a BA in Politics and International Relations from the University of Sussex, and is currently completing her NCTJ Diploma in Journalism.

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine search
Total results: 456

Articles by Marisa Woutersen

Hikma warns SCOTUS of ‘imminent threat’ for generic competition under ‘skinny label’ rules
Americas
Hikma warns SCOTUS of ‘imminent threat’ for generic competition under ‘skinny label’ rules
British pharma giant says that a Federal Circuit decision could stifle competition by lowering the bar for proving patent infringement | Earlier ruling ‘nullifies a statutory mechanism for expediting access to generic drugs and breaks sharply with precedent on inducement’ says UK pharma company.   20 February 2025
Apple voids Omni MedSci wearable tech patent
Americas
Apple voids Omni MedSci wearable tech patent
Patent Trial and Appeal Board rules all challenged claims were unpatentable | Decision follows Federal Circuit review that revived Apple’s challenge.   18 February 2025
Courtroom report: Regeneron’s $6bn biosimilar battle against Mylan
Americas
Courtroom report: Regeneron’s $6bn biosimilar battle against Mylan
The company’s Eylea treatment patent faced intense scrutiny as the US Federal Circuit heard Williams & Connolly, RMMS Legal, and McGuireWoods argue over criticality, stability, and validity.   13 February 2025
Americas
Fed Circ raises ‘gamesmanship’ fears in rare patent term dispute
Oral hearings heard the USPTO side with MSD (Merck) over a term extension for a reissued patent, in a case set to have huge implications for pharma market exclusivity, reports Marisa Woutersen.   6 February 2025
Europe
UK court upholds EU SPC precedent, rejecting MSD’s appeal
UK court confirms it cannot depart from CJEU law | SPC application for multiple sclerosis treatment rejected | Judges stress that any change to the SPC framework needs legislative reform not interpretation.   30 January 2025
Americas
Fish & Richardson doubles down in Chicago with new office
Five-strong team to open new location in the spring | Office will be led by experienced litigators and patent specialists bringing pharma, biologics, medical devices, femtech, and technology expertise to Chicago.   30 January 2025
Europe
Dutch court axes Biogen’s MS patent, clearing way for generics
Court cites lack of inventiveness and failure to meet reproducibility standards | Decision part of broader international litigation with mixed rulings | Generics still barred from selling products until early February.   28 January 2025
Americas
Fed Circ grants Teva temporary pause in Orange Book feud
Teva insisted panel’s narrow interpretation of ‘claims the drug’ will have a seismic effect on the Orange Book | Stay granted while en banc rehearing is under question | Decision could reshape patent listing standards and impact the availability of generic drugs.   23 January 2025
Europe
Takeda loses AMR treatment patent used in kidney transplants
Company faces setback as EPO revokes patent for a C1-esterase inhibitor treatment | Patent aims at preventing antibody-mediated rejection in kidney transplant patients | Court cites insufficient clinical trial data.   9 January 2025
Americas
Labcorp's bid to invalidate Ravgen's DNA testing patent hits roadblock
Biotech walks away with another win as Fed Circ upholds PTAB decision | Labcorp’s attempt to overturn $373m verdict fails | Court finds Ravgen’s method for preserving DNA in blood samples not obvious.   7 January 2025

Not finding what you're looking for, please try resetting your applied search and filters,
or try the full site search.